AneurysmbCANNCT06689410

Multimodal Biocollection Linked to the French Register of Intracranial Aneurysms

A study testing blood or saliva sample in people with Aneurysm and Brain Aneurysm, run by Nantes University Hospital at 26 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts

Official record

Search all trials

Trial summary

The purpose of the bCAN study is to create a prospective collection of multimodal data and human samples, linked to the French Intracranial Aneurysm Registry (FRAN). The aim of bCAN is to enable risk stratification of ruptured ICAs by redefining "intracranial aneurysm disease". Read more about this study

Who is it for?: Ages 18 years and older
Conditions the study is for: Aneurysm, Brain Aneurysm, Congenital Disease
What is being tested?: blood or saliva sample
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 1,100 participants
Where: 26 sitesFrance
Study dates: 25 Mar 2025to 25 Mar 2027
Phase: Interventional
Are there results?: Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 years and older
All sexes
No healthy volunteers
Adult, Older adult

Who may be able to join

Any adult patient consulting for a definite and typical bifurcation AIC authenticated on MRI and/or cerebral arteriography
Aneurysm discovered less than a year ago, with initial imaging (MRI and/or CTA and DSA) available
Written consent obtained for study participation
Patient covered by a social security plan
Inclusion criteria for index and related cases (familial forms) of intracranial aneurysms (ICA):
Index case: Any adult patient consulting for a definite and typical bifurcation ICA presenting at least one other case with ICA related (child, parent, brother, sister) detected by MRI with at least one Time of Flight (TOF) sequence.

Show all 9Show fewer

Family relatives: children, parents, brothers, sisters, of legal age, of patients with a family history of definite, typical bifurcation AIC (≥ 4 affected), Screening to be performed using MRI with at least a Time of Flight (TOF) sequence.
Written consent to participate in the study
Patient and relatives covered by a social security plan

Who cannot join

Syndromic diagnosis known to cause ICA: Marfan syndrome, OSA with SMAD 3, Elhers Danlos syndrome type II and IV, Autosomal Dominant Cystic Fibrosis, Moya-Moya syndrome
AIC with : Dissecting or fusiform, Associated with arteriovenous malformation, Blister-like, Mycotic
Cerebral white matter pathology detected on MRI evoking : Col4a1 mutation
Patient under guardianship or conservatorship
Person under court protection
Contraindication to an MRI scan

Trial locations and contacts

26 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Romain BOURCIER, MD contact

33240165608

romain.bourcier@chu-nantes.fr

City, postcode or hospital

Sites recruiting now only

26 sites in 1 country

France26 sites, 26 recruiting

CHU Amiens
Amiens
Cyril CHIVOT, +33 3 22 08 80 10, cyril.chivot@chu-amiens.fr
Cyril CHIVOT
Not yet recruiting
CHU Angers
Angers
Vincent L'ALLINEC, +33 2 41 35 36 37, vincent.lallinec@chu-angers.fr
Vincent L'ALLINEC
Not yet recruiting
CHU Besançon
Besançon
Alessandra BIONDI, +33 3 81 66 81 66, abiondi@chu-besancon.fr
Alessandra BIONDI
Not yet recruiting
CHU Bordeaux Hôpital Pellegrin
Bordeaux
Gaultier MARNAT, +33 5 57 82 17 65, gaultier.marnat@chu-bordeaux.fr
Gaultier MARNAT
Recruiting
CHU de Brest
Brest
Jean-Christophe GENTRIC, +33 2 98 22 33 33, jean-christophe.gentric@chu-brest.fr
Recruiting
CHU Caen-Normandie
Caen
Charlotte BARBIER, +33 2 31 06 31 06, barbier-ch@chu-caen.fr
Charlotte BARBIER
Recruiting
CHU Clermont-Ferrand
Clermont-Ferrand, 63000
Géraud FORESTIER, +33 4 73 751 747, gforestier@chu-clermontferrand.fr
Géraud FORESTIER
Recruiting
CHU Limoges
Limoges
Aymeric ROUCHAUD, +33 2 32 70 82 41, aymeric.rouchaud@chu-limoges.fr
Aymeric ROUCHAUD
Not yet recruiting
APHM
Marseille
Jean-François HAK, +33 4 13 42 90 51, jean-francois.hak@ap-hm.fr
Jean-François HAK
Not yet recruiting
CHU de Montpellier
Montpellier
Cyril DARGAZANLI, +33 4 67 33 75 32, c-dargazanli@chu-montpellier.fr
Cyril DARGAZANLI
Not yet recruiting
CHRU de Nancy
Nancy
François ZHU, +333 83 85 85 85, f.zhu@chru-nancy.fr
François ZHU
Recruiting
Nantes University Hospital
Nantes, Loire-Atlantique, 44093
Romain BOURCIER, +33 2.40.16.56.08, romain.bourcier@chu-nantes.fr
Romain BOURCIER
Recruiting
GHU Paris - Hôpital Ste Anne
Paris
Olivier NAGGARA, +33 1 45 65 85 74, o.naggara@ch-sainte-anne.fr
Olivier NAGGARA
Recruiting
Hôpital Fondation Rothschild
Paris
Jean-Philippe DESILLES, +33 1 32 70 82 35, jpdesilles@for.paris
Jean-Philippe DESILLES
Not yet recruiting
Hôpital La Pitié Salpêtrière
Paris
Eimad SHOTAR, +33 1 84 82 73 66, eimad.shotar@aphp.fr
Eimad SHOTAR
Not yet recruiting
Hôpital Lariboisière
Paris
Marc-Antoine LABEYRIE, +33 1 49 95 83 61, marc-antoine.labeyrie@aphp.fr
Marc-Antoine LABEYRIE
Not yet recruiting
CHU de Poitiers
Poitiers
Samy BOUCEBCI, +33 5 49 44 39 11, samy@boucebci.com
Samy BOUCEBCI
Not yet recruiting
CHU de Reims
Reims
Sébastien SOIZE, +33 3 26 78 87 64, ssoize@chu-reims.fr
Sébastien SOIZE
Not yet recruiting
CHU Rennes
Rennes
François EUGENE, +33 2 99 28 43 09, françois.eugene@chu-rennes.fr
François EUGENE
Recruiting
CHU de Rouen
Rouen
Julien BUREL, +33 2 32 88 82 41, julien.burel@chu-rouen.fr
Julien BUREL
Recruiting
CHU St Etienne
Saint-Etienne
Marina SACHET, +33 4 77 82 94 52, Marina.Sachet@chuse.fr
Marina SACHET
Not yet recruiting
Hôpitaux Universitaires de Strasbourg
Strasbourg
Raoul POP, +33 3 88 12 78 71, raoul.pop@chru-strasbourg.fr
Raoul POP
Not yet recruiting
Hôpital Foch
Suresnes
Arturo CONSOLI, +33 1 45 06 29 24, a.consoli@hopital-foch.com
Arturo CONSOLI
Not yet recruiting
HIA Sainte-Anne
Toulon
Quentin HOLAY, +33 4 83 16 20 10, quentin.holay@intradef.gouv.fr
Quentin HOLAY
Not yet recruiting
CHU de Toulouse
Toulouse
Christophe COGNARD, +33 5 61 77 23 39, cognard.c@chu-toulouse.fr
Christophe COGNARD
Not yet recruiting
CHRU Tours Hôpital Bretonneau
Tours
Kevin JANOT, +33 2 47 47 47 25, kevin.janot@univ-tours.fr
Kevin JANOT
Recruiting

Other trials in France

About this study

The purpose of the bCAN study is to create a prospective collection of multimodal data and human samples, linked to the French Intracranial Aneurysm Registry (FRAN).

The aim of bCAN is to enable risk stratification of ruptured ICAs by redefining "intracranial aneurysm disease". The description of genotypically and phenotypically specific subgroups of cases will pave the way for improved patient management based on new diagnostic/prognostic strategies among AIC carriers, either in a familial context, or at the level of the general population.

Read the detailed description

The main objective of bCAN study is to build a predictive model of intracranial aneurysm phenotypes through the combination of information on genetic mutations, imaging findings and ICA rupture characteristics.

The secondary objectives of the bCAN study are (i) to study morphological characterization of ICA and vascular bifurcations, (ii) to deepen knowledge of genotype/clinical and biological phenotype relationships according to the genes identified in the different families, (iii) to research and validate the relationships between genotypes and phenotypes (including rupture) of ICA in a large population of sporadic ICA cases.

Conditions: Aneurysm, Brain Aneurysm, Congenital Disease
Being tested: blood or saliva sample
Keywords: intracranial aneurysm, phenotype, genetics, imaging, multimodal data
Medical subject headings: Aneurysm, Intracranial Aneurysm, Congenital, Hereditary, and Neonatal Diseases and Abnormalities

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

blood or saliva sampleOther
Collection of blood or saliva

Study groups in NCT06689410
Study group	Role	What they receive
ICA cases	Other	Any adult patient consulting for a definite and typical bifurcation AIC authenticated on MRI and/or cerebral arteriography Receives: Other: blood or saliva sample

What is being measured

The primary outcome is the main question the study is designed to answer.

Performance of a predictive model allowing the classification of ICA subphenotypes
The performance of a predictive model allowing the classification of ICA subphenotypes will be analysed through the study of genetic results, quantitative features extracted from imaging and clinical data on rupture
Measured: 36 months

Secondary outcomes (4)

Characterization of arterial bifurcations
Quantitative morphological measurements of arterial bifurcations assessed using image processing tools enabling automatic characterization (artery diameters (in mm); artery cross-sections (in mm²); angles separating arteries (in degrees)
Measured: 36 months
Characterization of aneurysmal sacs
Quantitative morphological measurements of aneurysmal sacs assessed using image processing tools enabling automatic characterization (volume (in mm³); external surface area of the envelope (mm²); neck area (mm²))
Measured: 36 months
Screening of genetic mutations
Presence of genetic mutations in patients with intracranial aneurysms compared with a reference population, but also in a familial context. Genetic variations will be studied by whole exome sequencing
Measured: 36 months
Correlation between genotypes and phenotypes
Correlations between genetic mutations and the different clinical and biological phenotypes described in patients with sporadic ICA
Measured: 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

25 Mar 202525 Mar 2027

First posted14 Nov 2024
Study start25 Mar 2025
Primary completion25 Mar 2027 (estimated)
Study completion25 Mar 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for AneurysmStudies of the same condition, open and under way.
More trials run by Nantes University HospitalThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Other
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 1,100 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT06689410
Sponsor's protocol ID: RC24_0512
Acronym: bCAN
Status last verified: Apr 2026
First submitted: 31 Oct 2024
Last updated: 2 Sep 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: Undecided

Interested in taking part?

Romain BOURCIER, MD

33240165608

romain.bourcier@chu-nantes.fr

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
RecruitingObservational study
Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal
Not yet recruitingObservational study
Efficacy of Aflibercept (8 mg) With Sequential Laser Photocoagulation for Macular Edema Secondary to Retinal Artery Macroaneurysm: Retrospective Study"
Retinal Arterial Macroaneurysm
Not yet recruitingPhase 1/2
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Aneurysmal Subarachnoid Hemorrhage

All Aneurysm trials

Study at a glance

From the registry record, last updated by the sponsor on 2 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Multimodal Biocollection Linked to the French Register of Intracranial Aneurysms
ClinicalTrials.gov ID: NCT06689410
Acronym / sponsor ID: bCAN / RC24_0512
Conditions: Aneurysm, Brain Aneurysm, Congenital Disease
Keywords: intracranial aneurysm, phenotype, genetics, imaging, multimodal data
Study type: Interventional
Recruitment status: Recruiting
Enrolment: 1,100 participants (estimated)
Lead sponsor: Nantes University HospitalUniversity, hospital or other
Collaborators: Federation of Medical Specialties
Study start: 25 Mar 2025 (actual)
Primary completion: 25 Mar 2027 (estimated)
Study completion: 25 Mar 2027 (estimated)
First posted: 14 Nov 2024 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

The purpose of the bCAN study is to create a prospective collection of multimodal data and human samples, linked to the French Intracranial Aneurysm Registry (FRAN).

Detailed description

Study design

Primary purpose: Other
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1

Arm	Type	Receives
ICA cases	Other	Other: blood or saliva sampleAny adult patient consulting for a definite and typical bifurcation AIC authenticated on MRI and/or cerebral arteriography

Who may qualify

Ages: 18 years and older
Sex: All
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (9 listed)

Any adult patient consulting for a definite and typical bifurcation AIC authenticated on MRI and/or cerebral arteriography
Aneurysm discovered less than a year ago, with initial imaging (MRI and/or CTA and DSA) available
Written consent obtained for study participation
Patient covered by a social security plan
Inclusion criteria for index and related cases (familial forms) of intracranial aneurysms (ICA):

Key exclusion criteria (6 listed)

Syndromic diagnosis known to cause ICA: Marfan syndrome, OSA with SMAD 3, Elhers Danlos syndrome type II and IV, Autosomal Dominant Cystic Fibrosis, Moya-Moya syndrome
AIC with : Dissecting or fusiform, Associated with arteriovenous malformation, Blister-like, Mycotic
Cerebral white matter pathology detected on MRI evoking : Col4a1 mutation
Patient under guardianship or conservatorship
Person under court protection

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
blood or saliva sampleCollection of blood or saliva	Other	ICA cases

Primary outcome

Performance of a predictive model allowing the classification of ICA subphenotypes
Time frame: 36 months
The performance of a predictive model allowing the classification of ICA subphenotypes will be analysed through the study of genetic results, quantitative features extracted from imaging and clinical data on rupture

4 secondary outcomes

Characterization of arterial bifurcations
Time frame: 36 months
Characterization of aneurysmal sacs
Time frame: 36 months
Screening of genetic mutations
Time frame: 36 months
Correlation between genotypes and phenotypes
Time frame: 36 months

Results and safety

This study is still under way. Results are not available in the source record yet.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 2 Sep 2026.
Individual participant dataSharing planned: Undecided

Related trials for Aneurysm

Not yet recruitingObservational study
Pilot Study on the Effectiveness and Safety of OPTILENE® SILVER MESH ELASTIC in Prevention of Surgical Site Infection (SSI) and Incisional Hernia (IH)
Abdominal Aortic Aneurysm, Morbid Obesity
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
RecruitingObservational study
Determining the Clinical Impact and Prevalence of Hemorrhagic Subtypes in Perimesencephalic Subarachnoid Hemorrhage
Subarachnoid Hemorrhage, Spontaneous, Subarachnoid Hemorrhage, Aneurysmal
Not yet recruitingObservational study
Efficacy of Aflibercept (8 mg) With Sequential Laser Photocoagulation for Macular Edema Secondary to Retinal Artery Macroaneurysm: Retrospective Study"
Retinal Arterial Macroaneurysm
Not yet recruitingPhase 1/2
Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)
Aneurysmal Subarachnoid Hemorrhage

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.

Romain BOURCIER, MD contact

33240165608

romain.bourcier@chu-nantes.fr

Romain BOURCIER, MD principal investigator

Nantes University Hospital

26 sites in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

A study testing blood or saliva sample in people with Aneurysm and Brain Aneurysm, run by Nantes University Hospital at 26 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 26 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Romain BOURCIER, MD (33240165608, romain.bourcier@chu-nantes.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Performance of a predictive model allowing the classification of ICA subphenotypes (time frame: 36 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06689410.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Sep 2026.